Patient Access & Affordability
  • About
    • Mission
    • Who We Are
    • Professional Advisory Council
    • Patient Advisors
    • Members
    • Funding
    • Contact
  • Resources
    • Blog
    • Watch & Listen
    • Surveys
  • Publications
    • Research Briefings
    • Current Issues
    • Fast Facts
    • Policy Platform
  • Working Groups
    • Benefit Design
    • Rare Disease Health Technology Assessment
      • Featured Work
    • Biosimilars & Complex Generics
  • ICERWATCH
    • What is ICER?
    • ICER Glossary
    • Analysis and Commentary
    • Public Comments
Select Page
PRESS RELEASE: Patient Group Releases Special Report on Biosimilar Market and Trends

PRESS RELEASE: Patient Group Releases Special Report on Biosimilar Market and Trends

Jan 25, 2023

New report analyzes patient impact of game-changing biosimilars, including the introduction of competing biosimilars for Humira   WASHINGTON — Patients Rising, a non-profit organization advocating on behalf of patients with chronic and rare diseases, today released...
ICER’s Latest: A draft evidence report on treatments for vasomotor symptoms of menopause

ICER’s Latest: A draft evidence report on treatments for vasomotor symptoms of menopause

Oct 20, 2022

On October 11, 2022 2021, ICER released a draft evidence report, “Fezolinetant for Moderate to Severe Vasomotor Symptoms Associated with Menopause.”  This is the first step in ICER’s assessment process that is current scheduled to conclude with the release of a final...
Op-Ed: Medicare’s cuts to home health are a step in the wrong direction

Op-Ed: Medicare’s cuts to home health are a step in the wrong direction

Oct 12, 2022

By Terry WilcoxCo-founder and CEO, Patients Rising My grandmother lived at the top of a hill overlooking the magical mountains and valleys of the Ozarks until the day we literally had to drag her off of it. Our family was spread out across Texas and California working...
ICER’s Latest: A draft evidence report on gene therapies for Hemophilia A and B

ICER’s Latest: A draft evidence report on gene therapies for Hemophilia A and B

Sep 28, 2022

On September 13, 2022 2021, ICER released a new draft evidence report, “Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in December...
ICER’s Latest: A draft evidence report on medications for obesity management

ICER’s Latest: A draft evidence report on medications for obesity management

Jul 25, 2022

On July 13, 2022 2021, ICER released its draft evidence report, “Medications for Obesity Management.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in October 2022. ICER’s report reviews four medicines...
« Older Entries

Categories

  • Blog
  • Comments
  • ICERWatch
  • News
  • Opinion
  • QALY
  • Research
  • Resources
  • Statements
  • Uncategorized
  • Video

IPAA

700 12th St. NW, Suite 700
Washington, DC 20005
202-750-1186 |  info@accessandaffordability.org

The Patient Access & Affordability Project is a program of Patients Rising, a national 501(c)3 nonprofit organization, and is governed by the Patients Rising Board of Directors.

  • Facebook
  • Twitter
  • RSS